483 related articles for article (PubMed ID: 28130634)
1. X-linked hypophosphatemia and growth.
Fuente R; Gil-Peña H; Claramunt-Taberner D; Hernández O; Fernández-Iglesias A; Alonso-Durán L; Rodríguez-Rubio E; Santos F
Rev Endocr Metab Disord; 2017 Mar; 18(1):107-115. PubMed ID: 28130634
[TBL] [Abstract][Full Text] [Related]
2. Hypophosphatemia and growth.
Santos F; Fuente R; Mejia N; Mantecon L; Gil-Peña H; Ordoñez FA
Pediatr Nephrol; 2013 Apr; 28(4):595-603. PubMed ID: 23179196
[TBL] [Abstract][Full Text] [Related]
3. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.
Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB
J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835
[TBL] [Abstract][Full Text] [Related]
4. Impaired Growth Plate Maturation in XLH Is due to Both Excess FGF23 and Decreased 1,25-Dihydroxyvitamin D Signaling.
Yadav PS; Kobelski MM; Martins JS; Tao T; Liu ES; Demay MB
Endocrinology; 2023 Nov; 165(1):. PubMed ID: 38066669
[TBL] [Abstract][Full Text] [Related]
5. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
7. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
[TBL] [Abstract][Full Text] [Related]
8. The expanding family of hypophosphatemic syndromes.
Carpenter TO
J Bone Miner Metab; 2012 Jan; 30(1):1-9. PubMed ID: 22167381
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of PHEX Mutations and FGF23 Profiles in a Taiwanese Cohort With X-Linked Hypophosphatemia Including 102 Patients.
Su PH; Yu JS; Wu YZ; Tsai YS; Lo FS; Lin JL; Chao MC; Hsu CC; Ke YY; Chiu PC; Chen JC; Huang YH; Lin SP; Chou YY; Ting WH; Wang SY; Chiu CF; Huang YC; Hsiao HP; Lin CH; Wang CH; Bau DT; Lin CY
In Vivo; 2024; 38(1):341-350. PubMed ID: 38148081
[TBL] [Abstract][Full Text] [Related]
10. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
11. Blocking FGF23 signaling improves the growth plate of mice with X-linked hypophosphatemia.
Fuente R; Pastor-Arroyo EM; Gehring N; Oro Carbajosa P; Alonso-Durán L; Zderic I; Tapia-Dean J; Hamid AK; Bettoni C; Santos F; Wagner CA; Rubio-Aliaga I
J Endocrinol; 2023 Sep; 259(1):. PubMed ID: 37439399
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
13. Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH.
Liu ES; Thoonen R; Petit E; Yu B; Buys ES; Scherrer-Crosbie M; Demay MB
Endocrinology; 2018 May; 159(5):2165-2172. PubMed ID: 29635291
[TBL] [Abstract][Full Text] [Related]
14. FGF23 and its role in X-linked hypophosphatemia-related morbidity.
Beck-Nielsen SS; Mughal Z; Haffner D; Nilsson O; Levtchenko E; Ariceta G; de Lucas Collantes C; Schnabel D; Jandhyala R; Mäkitie O
Orphanet J Rare Dis; 2019 Feb; 14(1):58. PubMed ID: 30808384
[TBL] [Abstract][Full Text] [Related]
15. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia.
Leifheit-Nestler M; Kucka J; Yoshizawa E; Behets G; D'Haese P; Bergen C; Meier M; Fischer DC; Haffner D
Bone; 2017 Oct; 103():224-232. PubMed ID: 28728941
[TBL] [Abstract][Full Text] [Related]
16. Cellular and Molecular Alterations Underlying Abnormal Bone Growth in X-Linked Hypophosphatemia.
Fuente R; García-Bengoa M; Fernández-Iglesias Á; Gil-Peña H; Santos F; López JM
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055123
[TBL] [Abstract][Full Text] [Related]
17. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
18. A PAI-1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D-resistant rickets model mouse.
Qian C; Ito N; Tsuji K; Sato S; Kikuchi K; Yoshii T; Miyata T; Asou Y
FEBS Open Bio; 2024 Feb; 14(2):290-299. PubMed ID: 38050660
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T
J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316
[TBL] [Abstract][Full Text] [Related]
20. Congenital Conditions of Hypophosphatemia Expressed in Adults.
Marcucci G; Brandi ML
Calcif Tissue Int; 2021 Jan; 108(1):91-103. PubMed ID: 32409880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
